Serizawa I - Search Results

1

Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.

Parekh VV, Singh AK, Wilson MT, Olivares-Villagómez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L, Wang CR, Joyce S, Van Kaer L. Parekh VV, et al. Among authors: serizawa i. J Immunol. 2004 Sep 15;173(6):3693-706. doi: 10.4049/jimmunol.173.6.3693. J Immunol. 2004. PMID: 15356115

2

Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.

Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L. Singh N, et al. Among authors: serizawa i. J Immunol. 1999 Sep 1;163(5):2373-7. J Immunol. 1999. PMID: 10452969

3

The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.

Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L. Hong S, et al. Among authors: serizawa i. Nat Med. 2001 Sep;7(9):1052-6. doi: 10.1038/nm0901-1052. Nat Med. 2001. PMID: 11533710

4

Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice.

Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, Van Kaer L. Hong S, et al. Among authors: serizawa i. Immunol Rev. 1999 Jun;169:31-44. doi: 10.1111/j.1600-065x.1999.tb01304.x. Immunol Rev. 1999. PMID: 10450506 Review.

5

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K, Uemura Y, Aoki Y, Kaga S, Minota S, Tanaka T, Yamaguchi Y, Kobayashi T, Serizawa I. Watanabe T, et al. Among authors: serizawa i. Clin Immunol. 2006 Sep;120(3):247-59. doi: 10.1016/j.clim.2006.05.006. Epub 2006 Jun 22. Clin Immunol. 2006. PMID: 16797237

6

An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model.

Kobayashi T, Miura T, Haba T, Sato M, Serizawa I, Nagai H, Ishizaka K. Kobayashi T, et al. Among authors: serizawa i. J Immunol. 2000 Apr 1;164(7):3855-61. doi: 10.4049/jimmunol.164.7.3855. J Immunol. 2000. PMID: 10725747

7

Functional natural killer T cells in experimental mouse strains, including NK1.1- strains.

Serizawa I, Koezuka Y, Amao H, Saito TR, Takahashi KW. Serizawa I, et al. Exp Anim. 2000 Jul;49(3):171-80. doi: 10.1538/expanim.49.171. Exp Anim. 2000. PMID: 11109539 Free article.

8

The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model.

Ohno H, Uemura Y, Murooka H, Takanashi H, Tokieda T, Ohzeki Y, Kubo K, Serizawa I. Ohno H, et al. Among authors: serizawa i. Eur J Immunol. 2008 Jan;38(1):283-91. doi: 10.1002/eji.200737199. Eur J Immunol. 2008. PMID: 18085662 Free article.

9

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells.

Nakagawa R, Serizawa I, Motoki K, Sato M, Ueno H, Iijima R, Nakamura H, Shimosaka A, Koezuka Y. Nakagawa R, et al. Among authors: serizawa i. Oncol Res. 2000;12(2):51-8. doi: 10.3727/096504001108747521. Oncol Res. 2000. PMID: 11132924

10

The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis.

Uemura Y, Ohno H, Ohzeki Y, Takanashi H, Murooka H, Kubo K, Serizawa I. Uemura Y, et al. Among authors: serizawa i. J Neuroimmunol. 2008 Mar;195(1-2):73-80. doi: 10.1016/j.jneuroim.2008.01.015. Epub 2008 Apr 2. J Neuroimmunol. 2008. PMID: 18378004

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters